npj Precision Oncology
An international, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications to clinical medicine.
Towards a New Diagnostic to Identify Lung Cancer Patients Who Respond to Immunotherapy by Analyzing Blood-born microRNAs
Timothy Rajakumar, MD, PhD & Bruno Steinkraus, PhD
Target cancer-associated fibroblasts to potentiate PARP inhibitors
Besides eradicating tumour cells with deficiencies for homologous recombination, PARP inhibitors can induce the activation of CAFs within the TME via NF-κB/CCL5 pathway. CCL5 blockade blunts the reprogramming of CAFs conditioned by PARP inhibitors and potentiates PARP inhibitors.
